The Delhi High Court has reserved its judgment in the high-profile Daiichi-Fortis case after fifty intensive court sessions. Specifically, Japanese drugmaker Daiichi Sankyo is seeking to enforce a massive Singapore tribunal arbitral award against former Fortis promoters. Consequently, the legal representatives of both parties concluded their arguments before Justice Subramonium Prasad. This long-running corporate war has significant implications for regulatory compliance in India.

The Core of the Daiichi-Fortis Case

Originally, a Singapore tribunal issued the award a decade ago due to fraud allegations in the 2008 Ranbaxy Laboratories sale. However, the interest on this award has now swollen the total outstanding debt to over ₹5,200 crore. To recover this money, Daiichi wanted to prevent the Singh brothers from diluting their stake in Fortis Healthcare. Unfortunately, several financial institutions invoked and sold the pledged shares to recover separate debts. Therefore, the case has evolved into a complex three-way battle among lenders, Fortis, and the Singh brothers.

Arguments on Asset Dissipation

During the hearings, senior advocate Arvind Nigam argued that Fortis allowed deliberate asset dissipation under the former promoters. Specifically, he questioned the sale of 186 million shares, pointing out that promoter shares require regulatory approval. Additionally, Nigam asserted that the compliance officer must authorize any such share transfers under Sebi rules.

Conversely, Fortis Healthcare vehemently denied any liability for the share transfers. Furthermore, the counsel for Fortis claimed that Daiichi failed to use available legal tools to protect its interests. Because of this inaction, Fortis argues that Daiichi cannot hold the hospital chain responsible for the missing assets.

Frequently Asked Questions

Q1: What is the main dispute in the Daiichi-Fortis case?

The dispute centers around Japanese drugmaker Daiichi Sankyo's effort to enforce a massive ₹5,200 crore arbitration award against the former promoters of Fortis Healthcare.

Q2: Why is Fortis Healthcare contesting the liability?

Fortis Healthcare argues that its compliance officer never approved any unencumbered share transfers. Furthermore, it asserts that Daiichi failed to use available legal tools earlier to protect its own interests.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. After 50 hearings, court reserves judgement in Daiichi-Fortis case - ETHealthworld


2. Delhi High Court Finds Fortis Healthcare Liable for Disappearing Promoter Shares - Business and Legal Reports